Healthcare stocks are moderately lower with the NYSE Healthcare
Sector Index declining 0.5% and shares of healthcare companies in
the S&P 500 also are off nearly 0.5% as a group.
In company news, Omeros (
) is holding on to a 14% gain in late Wednesday trade at $11.03 a
share, earlier climbing less than 20 cents of its 52-week high of
$11.85 after saying its OMS302 ophthalmology drug candidate is on
track for a commercial launch early next year.
The U.S. Food and Drug Administration currently is reviewing
OMS302 after recently accepting the company's new drug application
while the European Medicines Agency also is considering OMER's
marketing authorization application for the drug.
In a new research note today, Wedbush analyst Liana Moussatos
said she was boosting her fair value estimate on OMERs shares by $4
to $32 a share while maintaining an Outperform rating.
"With U.S. and EU regulators formally accepting OMS302 for
review, the time clock for approval begins," she said.
In other sector news,
(+) DCTH, FDA grants orphan drug designation for the company's
melphalan hydrochloride medication as a treatment for a form of
liver cancer. Melphalan for use with the Delcath Hepatic Delivery
System currently is not approved in the U.S.
(-) STEM, Prices public offering of 11.7 mln shares of common
stock at $1.45 each, generating $16.2 mln in gross proceeds.
Copyright (C) 2013 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.